Sumitomo Pharma announces authorization in Canada of Orgovyx for treatment prostate cancer
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Three-point improvement achieved in Sex Ratio at Birth from 904 in 2017-19 to 907 in 2018-20
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Lokavant provides clinical trial intelligence
The biopharmaceutical leader shared its expert perspective at the Equality Lounge at the G20 Summit
Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.
Aims to foster a Resilient and Sustainable Healthcare Ecosystem
Qualicaps is the third largest producer of hard capsules for oral dosage solutions
Traditional medicine effectively highlighted in all health and engagement working groups meeting and Ministry of Ayush acknowledges these efforts
Subscribe To Our Newsletter & Stay Updated